[Tickers Inside] 7 Solid Gainers Over the Last 5 Sessions

Stocks with 5 days of consecutive price advances. If you cannot see this email properly, please click [here]( --------------------------------------------------------------- Sponsor Message [New "Vertical" Technology Solves Solar Power's Major Flaw]( [See How Early Stage Investors in This Solar Tech Could Benefit]( --------------------------------------------------------------- January 30, 2023 From the desk of the Editor (5 Day Gainers Report) Dear Reader, We just identified 7 Five Day Gainers across all US Exchanges. If you are interested in any of these companies, we encourage you to do your own research and due diligence. Keep reading to see what we just uncovered... --------------------------------------------------------------- Sponsor Message ["TAKE THAT, CHINA!" USA Gains in EV Battery Arms Race]( you know each electric car battery requires 220 pounds of graphite - more than lithium, copper, or aluminum? China enjoyed a "near monopoly" in this vital ingredient... until the U.S. made a blockbuster announcement. Now one little-known company is set to play a crucial role in the booming $7 trillion EV revolution. [Get the full story on this new North American graphite opportunity]( --------------------------------------------------------------- [NewAmsterdam Pharma Company, NAMS]( Recent Analyst Action: Roanna Ruiz, analyst at SVB Securities, reiterates coverage on [NewAmsterdam Pharma Company (NAMS)](in the Healthcare sector with a Buy rating and a price target of $19.00 (1 week ago). - Recent Price: $$16.34 - Average Analyst Price Target: $21.33 (30.54%) - Market Cap: $$1.33B [TipRanks.com]( also reports that [NewAmsterdam Pharma Company](currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $21.33 . The target pricing ranges from a high forecast of $24.00 down to a low forecast of $19.00. [NewAmsterdam Pharma Company (NAMS)](’s last closing price was $$16.34 which would put the average price target at $$21.33. Here are 3rd party ratings for [NAMS](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: n/a - Zacks.com: Hold, Top 35% (86 out of 249) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Everyone knows America is nuts right now. But this is next-level crazy...]( Florida man pulls up to the service station… “Hacks” gas pump... And then THIS happens: [Click here to watch!]( --------------------------------------------------------------- [Xilio Therapeutics, XLO]( Recent Analyst Action: Michael Ulz, analyst at Morgan Stanley, reiterates coverage on [Xilio Therapeutics (XLO)](in the Healthcare sector with a Buy rating and a price target of $10.00 (3 days ago). - Recent Price: $$4.29 - Average Analyst Price Target: $9.75 (127.27%) - Market Cap: $$117.58M [TipRanks.com]( also reports that [Xilio Therapeutics](currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $9.75 . The target pricing ranges from a high forecast of $13.00 down to a low forecast of $7.00. [Xilio Therapeutics (XLO)](’s last closing price was $$4.29 which would put the average price target at $$9.75. Here are 3rd party ratings for [XLO](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: buy - Zacks.com: Hold, Top 33% (83 out of 249) [Click here for chart >>]( -------------------------------------------------------------------------- [Shattuck Labs, STTK]( Recent Analyst Action: Joseph Pantginis, analyst at H.C. Wainwright, reiterates coverage on [Shattuck Labs (STTK)](in the Healthcare sector with a Buy rating and a price target of $28.00 (2 weeks ago). - Recent Price: $$3.76 - Average Analyst Price Target: $23.00 (511.70%) - Market Cap: $$157.27M [TipRanks.com]( also reports that [Shattuck Labs](currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $23.00 . The target pricing ranges from a high forecast of $28.00 down to a low forecast of $20.00. [Shattuck Labs (STTK)](’s last closing price was $$3.76 which would put the average price target at $$23.00. Here are 3rd party ratings for [STTK](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak buy - Zacks.com: Hold, Top 33% (83 out of 249) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Why savvy Investors Are Looking Beyond Stocks Right Now]( Top equity research shops like Goldman Sachs are forecasting equity returns of only 4% in the next 5 years. One place investors are turning for diversification is the [art market](. It has a near-zero correlation to traditional assets, meaning when the stock market declines, art investments may not be affected. With [Masterworks](, it's easy for anyone to invest in art. Get started today with a special link. *See important [disclosures]( --------------------------------------------------------------- [Osisko Development, ODV]( Recent Analyst Action: Don DeMarco, analyst at National Bank, reiterates coverage on [Osisko Development (ODV)](in the Basic Materials sector with a Buy rating and a price target of $6.37 (2 weeks ago). - Recent Price: $$5.69 - Average Analyst Price Target: $6.56 (15.29%) - Market Cap: $$430.14M [TipRanks.com]( also reports that [Osisko Development](currently has 2 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $6.56 . The target pricing ranges from a high forecast of $6.75 down to a low forecast of $6.37. [Osisko Development (ODV)](’s last closing price was $$5.69 which would put the average price target at $$6.56. Here are 3rd party ratings for [ODV](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak buy - Zacks.com: Hold, Top 30% (74 out of 249) [Click here for chart >>]( -------------------------------------------------------------------------- [Amtech Systems, ASYS]( Recent Analyst Action: Mark Miller, analyst at Benchmark Co., reiterates coverage on [Amtech Systems (ASYS)](in the Industrial Goods sector with a Buy rating and a price target of $15.00 (1 month ago). - Recent Price: $$11.237 - Average Analyst Price Target: $15.00 (33.49%) - Market Cap: $$152.04M [TipRanks.com]( also reports that [Amtech Systems](currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $15.00 . The target pricing ranges from a high forecast of $15.00 down to a low forecast of $15.00. [Amtech Systems (ASYS)](’s last closing price was $$11.237 which would put the average price target at $$15.00. Here are 3rd party ratings for [ASYS](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: buy - Zacks.com: Hold, Top 27% (67 out of 249) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Huge Upside Potential With "Staggering" Solar Demand]( solar demand is "staggering" right now, according to Bloomberg. Solar installations are set to grow 30% this year alone. And the boom is just beginning, with increasing adoption of solar by commercial, non-profit, and public entities. With only 1% of commercial electricity demand served by on-site solar globally, there is HUGE opportunity for growth. [See How Investors Could Benefit]( --------------------------------------------------------------- [2seventy bio, TSVT]( Recent Analyst Action: Matthew Harrison, analyst at Morgan Stanley, reiterates coverage on [2seventy bio (TSVT)](in the Healthcare sector with a Buy rating and a price target of $28.00 (6 days ago). - Recent Price: $$13.21 - Average Analyst Price Target: $29.33 (122.03%) - Market Cap: $$502.40M [TipRanks.com]( also reports that [2seventy bio](currently has 7 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $29.33 . The target pricing ranges from a high forecast of $34.00 down to a low forecast of $28.00. [2seventy bio (TSVT)](’s last closing price was $$13.21 which would put the average price target at $$29.33. Here are 3rd party ratings for [TSVT](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: sell - Zacks.com: Buy, Top 33% (83 out of 249) [Click here for chart >>]( -------------------------------------------------------------------------- [Applied Tech, AIT]( Recent Analyst Action: Kenneth Newman, analyst at KeyBanc, reiterates coverage on [Applied Tech (AIT)](in the Industrial Goods sector with a Buy rating and a price target of $162.00 (3 days ago). - Recent Price: $$140.76 - Average Analyst Price Target: $164.00 (16.51%) - Market Cap: $$5.41B [TipRanks.com]( also reports that [Applied Tech](currently has 3 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $164.00 . The target pricing ranges from a high forecast of $170.00 down to a low forecast of $160.00. [Applied Tech (AIT)](’s last closing price was $$140.76 which would put the average price target at $$164.00. Here are 3rd party ratings for [AIT](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Hold, Top 37% (93 out of 249) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [The Lithium "Lie"]( you know each electric car battery requires 220 pounds of graphite - more than lithium, copper, or aluminum? China controls more than 90% of this vital ingredient. But the U.S. just classified graphite as "essential for America's National Defense"... and one little-known company is looking to win big in the energy war with China. [Find Out How Investors Can Benefit From the Energy War with China]( --------------------------------------------------------------- And there you have it--7 Five Day Gainers across all US Exchanges. Sincerely, Editor, MarketTickerPress.com Market Ticker Press Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. By opening and/or clicking a link containted within this email, you are reconfirming your opt-in status. You can unsubscribe at any time. MarketTickerPress.com part of Sandpiper Marketing Group | 1519 Mecklenburg Hwy | Unit 4 | Mt. Mourne | North Carolina | 28123 | United States | 877-411-9808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software